Neuronetics Inc.
STIM | NASDAQ
$2.92
+$0.07 (+2.46%)
Sep 22, 2026, 2:36 PM ET · Market open
Company Profile
Neuronetics, Inc. functions as a medical technology enterprise with commercialized products, specializing in the creation, enhancement, and global distribution of solutions for individuals experiencing neurohealth conditions, both within the U.S. and abroad. The company's flagship product is the NeuroStar Advanced Therapy System, an in-office, non-surgical, and non-pharmaceutical treatment option available for adult patients diagnosed with major depressive disorder. This sophisticated system utilizes transcranial magnetic stimulation (TMS) to generate a pulsed magnetic field, similar in strength to an MRI, which subsequently induces electrical currents. These currents are specifically engineered to activate brain areas that are key to mood regulation. Neuronetics distributes its offerings directly to psychiatrists through its dedicated sales and client support personnel. Established in 2001, the company's corporate headquarters are situated in Malvern, Pennsylvania.
Key Executives
| Name | Position |
|---|---|
| Daniel L. Reuvers | President, Chief Executive Officer & Director |
| Lisa Metzner-Rosas | Senior Vice President & Chief Marketing Officer |
| W. Andrew Macan | EVice President, Chief Legal Officer & Corporate Secretary |
| Cory S. Anderson | Executive Vice President & General Manager of Greenbrook |
| Francis X. Brown | Interim Principal Financial & Accounting Officer |
| Jeffrey S. Jones | Senior Vice President & Chief of Operations |
| Nir Naor | Executive VP, CFO, Corporate Secretary, Principal Financial and Accounting Officer & Treasurer |
| Robert Greene | Senior Vice President of Sales |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Aug 24, 2026 | SC 13D/A | [Amend] Filing |
| Aug 17, 2026 | 8-K | Current Report |
| Aug 17, 2026 | 4 | Filing |
| Aug 14, 2026 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Aug 11, 2026 | S-8 | Filing |
| Aug 11, 2026 | 10-Q | Quarterly Report |
| Aug 11, 2026 | 8-K | Current Report |
| Aug 04, 2026 | SC 13D/A | [Amend] Filing |
| Jul 23, 2026 | 4 | Filing |
| Jul 23, 2026 | 3 | Filing |
Neuronetics Inc.
| Country | United States |
| IPO Date | Jun 27, 2018 |
| Industry | Medical - Devices |
| Sector | Healthcare |
| Employees | 658 |
| CEO | Daniel L. Reuvers |
Contact Details
3222 Phoenixville Pike Malvern,
Pennsylvania 19355 United States
Stock Details
| Ticker Symbol | STIM |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001227636 |
| CUSIP Number | 64131A105 |
| ISIN Number | US64131A1051 |
| SIC Code | 3841 |
Add to Watchlist
Select watchlists to add or remove STIM